CrossRefPubMed 62. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS: Costimulation of anti-tumour immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992, 71: 1093–1102.CrossRefPubMed 63. Townsend SE, Allison

JP: Tumour rejection after direct costimulation of CD8+ Dactolisib purchase T cells by B7-transfected melanoma cells. Science 1993, 259: 368–370.CrossRefPubMed 64. Eberlein T, Rosenstein M, Rosenberg S: Regression of a disseminated syngeneic solid tumour by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med 1982, 156: 385–397.CrossRefPubMed 65. Rosenberg S, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumourinfiltrating lymphocytes. Science Entospletinib in vivo 1986, 233: 1318–1321.CrossRefPubMed 66. Overwijk W, Tsung A, Irvine K, Parkhurst

MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP: gp100/pmel 17 is a murine tumour rejection antigen: Induction of self reactive, tumouricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998, 188: 277–286.CrossRefPubMed 67. Rosenberg S, Terry W: Passive immunotherapy of cancer in animals and man. Adv Cancer Res 1977, 25: 323.CrossRefPubMed 68. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of patients with metastatic melanoma with autologous tumour-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994, 86: 1159–1166.CrossRefPubMed 69. Yee C, Thompson J, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD: Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med 2000, 192: 1637–1644.CrossRefPubMed 70. check details Dudley M, Wunderlich J, Nishimura

M, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF, Rosenberg SA: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001, http://www.selleck.co.jp/products/azd9291.html 24: 363–373.CrossRefPubMed 71. Dudley M, Wunderlich J, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, Rosenberg SA: A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002, 25: 243–251.CrossRefPubMed 72. North R: Cyclophosphamide-facilitated adoptive immunotherapy of an established tumour depends on elimination of tumour-induced suppressor T cells. J Exp Med 1982, 155: 1063–1074.CrossRefPubMed 73.